BIIB news, real time BIIB stock news, Biogen Inc news today

News

BIIB

172.10

+0.35%

0.60

MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too?

Barchart · 16h ago

Nasdaq 100 Movers: BIIB, MSTR

NASDAQ · 1d ago

Stifel Nicolaus Sticks to Its Buy Rating for Biogen (BIIB)

TipRanks · 1d ago

Biogen (BIIB) Valuation Check After Positive Neurology Data for Lecanemab and Zorevunersen

Simply Wall St · 1d ago

Seagate, Western Digital among additions to Nasdaq-100 on 12/22

TipRanks · 2d ago

Biogen’s New Study on BIIB145: A Potential Game-Changer for MS Treatment?

TipRanks · 2d ago

Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves

Benzinga · 2d ago

Weekly Report: what happened at BIIB last week (1208-1212)?

Weekly Report · 2d ago

Reported Friday, Nasdaq-100 Index Reconstituted As Alnylam, Ferrovial, Insmed, Monolithic Power, Seagate And Western Digital Join, While Biogen, CDW, GlobalFoundries, Lululemon, ON Semiconductor And Trade Desk Exit

Benzinga · 2d ago

Who Made It to the Nasdaq-100 (NDX) Annual Reshuffle – and Who Did Not?

TipRanks · 2d ago

Biogen: Alzheimer's Disease Treatment Needs More Real-World Data

Seeking Alpha · 3d ago

Nasdaq adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22

TipRanks · 3d ago

Wall Street Analysts Are Bullish on Top Healthcare Picks

TipRanks · 3d ago

Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions

Seeking Alpha · 4d ago

Nasdaq-100 Index Reconstitution Adds Six New Companies, Removes Six Others Effective Dec. 22

NASDAQ · 5d ago

NASDAQ INC: BIOGEN, CDW CORPORATION, GLOBALFOUNDRIES , LULULEMON ATHLETICA, ON SEMICONDUCTOR, TRADE DESK WILL BE REMOVED FROM NASDAQ 100 INDEX

Reuters · 5d ago

Buy/Sell: Wall Street’s top 10 stock calls this week

TipRanks · 5d ago

Biogen Price Target Raised to $156.00/Share From $149.00 by Morgan Stanley

Dow Jones · 5d ago

Biogen Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones · 5d ago

Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $156

Benzinga · 5d ago

Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.

About BIIB

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).